High-rolling financiers have actually placed themselves bullish on Biogen (NASDAQ: BIIB), and it is essential for retail traders to bear in mind.
This activity concerned our attention today through Benzinga’s tracking of openly offered alternatives information. The identities of these financiers doubt, however such a considerable relocation in BIIB frequently signifies that somebody has fortunate details.
Today, Benzinga’s alternatives scanner identified 8 alternatives trades for Biogen. This is not a common pattern.
The belief amongst these significant traders is divided, with 75% bullish and 25% bearish. Amongst all the alternatives we recognized, there was one put, totaling up to $34,010, and 7 calls, amounting to $594,072.
Forecasted Rate Variety
Evaluating the Volume and Open Interest in these agreements, it appears that the huge gamers have actually been considering a rate window from $150.0 to $180.0 for Biogen throughout the previous quarter.
Volume & & Open Interest Trends
Examining the volume and open interest is a tactical action in alternatives trading. These metrics clarified the liquidity and financier interest in Biogen’s alternatives at defined strike rates. The upcoming information pictures the change in volume and open interest for both calls and puts, connected to Biogen’s considerable trades, within a strike cost spectrum from $150.0 to $180.0 over the preceding 1 month.
Biogen Call and Put Volume: 30-Day Introduction
Noteworthy Options Activity:
| Sign | PUT/CALL | Trade Type | Belief | Exp. Date | Ask | Quote | Rate | Strike Rate | Overall Trade Rate | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BIIB | CALL | TRADE | BULLISH | 12/19/25 | $ 5.7 | $ 4.4 | $ 5.5 | $ 175.00 | $ 247.5 K | 1.1 K | 506 |
| BIIB | CALL | TRADE | BULLISH | 12/18/26 | $ 25.7 | $ 22.5 | $ 24.6 | $ 180.00 | $ 78.7 K | 20 | 1 |
| BIIB | CALL | SWEEP | BULLISH | 01/16/26 | $ 20.0 | $ 19.1 | $ 20.0 | $ 150.00 | $ 70.0 K | 952 | 109 |
| BIIB | CALL | TRADE | BULLISH | 12/18/26 | $ 29.3 | $ 26.8 | $ 29.3 | $ 170.00 | $ 58.6 K | 22 | 21 |
| BIIB | CALL | TRADE | BULLISH | 01/16/26 | $ 21.0 | $ 20.5 | $ 21.0 | $ 150.00 | $ 52.5 K | 952 | 50 |
About Biogen
Biogen is a recognized biopharmaceutical business concentrated on treatments for neurological illness and unusual illness. Its decreasing numerous sclerosis franchise is its biggest profits generator and contributed 45% of overall profits in 2024. Biogen likewise produces considerable profits from its CD20 partnership arrangements with Roche (18% of overall in 2024), that includes oncology drugs Rituxan and Gazyva and numerous sclerosis drug Ocrevus. Biogen’s more recent franchises consist of Spinraza (spine muscular atrophy, with partner Ionis), Leqembi (Alzheimer’s illness, collabroation profits from its partner Eisai), Skyclarys (Friedreich’s ataxia, Reata), Zurzuvae (postpartum anxiety, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
After an extensive evaluation of the alternatives trading surrounding Biogen, we relocate to take a look at the business in more information. This consists of an evaluation of its existing market status and efficiency.
Existing Position of Biogen
- With a trading volume of 947,967, the cost of BIIB is down by -0.38%, reaching $166.92.
- Existing RSI worths suggest that the stock is might be overbought.
- Next revenues report is set up for 86 days from now.
What Experts Are Stating About Biogen
Over the previous month, 3 market experts have actually shared their insights on this stock, proposing a typical target cost of $189.67.
Turn $1000 into $1270 in simply 20 days?
20-year professional alternatives trader exposes his one-line chart strategy that reveals when to purchase and offer. Copy his trades, which have actually had balanced a 27% earnings every 20 days. Click on this link for gain access to
* An expert from Bernstein has actually chosen to keep their Market Perform score on Biogen, which presently sits at a rate target of $157.
* In a favorable relocation, an expert from Stifel has actually updated their score to Purchase and changed the cost target to $202.
* Constant in their examination, an expert from RBC Capital keeps a Outperform score on Biogen with a target cost of $210.
Options trading provides greater threats and possible benefits. Astute traders handle these threats by continuously informing themselves, adjusting their methods, keeping an eye on numerous indications, and keeping a close eye on market motions. Stay notified about the most recent Biogen alternatives trades with real-time notifies from Benzinga Pro.